

Sheet 1 of 10		
Form PTO-1449 U.S. Department of Commerce Information Disclosure Statement	DOCKET NO. 046483-6001US13(01088)	APPLN. NO. To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	GROUP: Not Yet Assigned

U.S. PATENT DOCUMENTS							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if appropriate	
	5,359,046	10/25/1994	Capon et al.				
	5,686,281	11/11/1997	Roberts				
	5,712,149	01/27/1998	Roberts				
	5,874,240	02/23/1999	Ni et al.				
	5,906,936	05/25/1999	Eshhar, et al.				
	6,103,521	08/15/2000	Capon et al.				
	6,319,494	11/20/2001	Capon et al.				
	6,355,779	03/12/2002	Goodwin et al.				
	6,410,319	06/25/2002	Raubitschek, et al.				
	US2003/060444	03/27/2003	Finney et al.				
	US2003/0077249	04/24/2003	Bebbington et al.				
	6,569,997	05/27/2003	Kwon				
	US2003/0148982	08/07/2003	Brenner et al.				
	US2004/038886	02/26/2004	Finney et al.				
	US2004/0043401	03/04/2004	Sadelain, et al.				
	US2005/0113564	05/26/2005	Campana, et al.				
	US2005/0129671	06/16/2005	Cooper et al.				
	7,049,136	05/23/2006	Seed et al.				
	7,052,906	05/30/2006	Lawson et al.				
	7,070,995	07/04/2006	Jensen				
	7,265,209	09/04/2007	Jensen				
	7,319,143	01/15/2008	Gross, et al.				
	7,320,787	01/22/2008	Seed et al.				
	US2008/0131415	06/05/2008	Riddell et al.				

Examiner Signature: /Michael Burkhardt/	Date Considered: 04/18/2016
---	---

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Sheet 2 of 10		
Form PTO-1449 U.S. Department of Commerce Information Disclosure Statement	DOCKET NO. 046483-6001US13(01088)	APPLN. NO. To Be Assigned
APPLICANT: Carl H. June et al.		GROUP: Not Yet Assigned
FILING DATE: Herewith		

	7,446,190	11/04/2008	Sadelain, et al.			
	7,446,191	11/04/2008	Jensen			
	7,514,537	04/07/2009	Jensen			
	US2009/0257994	10/15/2009	Jensen			
	7,741,465	06/22/2010	Eshhar et al.			
	US2010/0233200	09-16-2010	Medin			
	US2011/0052554	03/03/2011	Zakrzewski et al.			
	7,994,298	08/09/2011	Zhang et al.			
	US2012/0148552	06/14/2012	Jensen			
	8,211,422	07/03/2012	Esshar et al.			
	8,252,914	08/28/2012	Zhang et al.			
	8,389,282	03/05/2013	Sadelain et al.			
	8,399,645	03/19/2013	Campana et al.			
	US2013/071414	03/21/2013	Dotti et al.			
	8,465,743	06/01/2013	Rosenberg, et al.			
	US2013/0149337	06/13/2013	Cooper, et al.			

FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Subclass	Translation Yes/No/Abstract	
	WO1992/015322	17 Sep 1992	PCT				
	WO/1995/30014	09 Nov 1995	PCT				
	WO1996/23814	08 Aug 1996	PCT				
	WO1996/24671	15 Aug 1996	PCT				
	WO/1997/015669	01 May 1997	PCT				
	WO/1997/23613	03 Jul 1997	PCT				
	WO1998/18809	07 May 1998	PCT				
	WO1999/00494	07 Jan 1999	PCT				

Examiner Signature: /Michael Burkhart/	Date Considered: 04/18/2016
---	---------------------------------------

Sheet 3 of 10		
Form PTO-1449 U.S. Department of Commerce Information Disclosure Statement	DOCKET NO. 046483-6001US13(01088)	APPLN. NO. To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	GROUP: Not Yet Assigned

FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Subclass	Translation Yes/No/Abstract	
	WO1999/57268	11 Nov 1999	PCT				
	WO/2000/14257	16.03.2000	PCT				
	WO/2002/077029	03 Oct 2002	PCT				
	WO/2002/033101	25 Apr 2002	PCT				
	WO/2002/088334	07 Nov 2002	PCT				
	EP 0574512B1	05 Feb 2003	EP				
	EP1226244	28 July 2004	EP				
	WO2005/019429	03 Mar 2005	PCT				
	EP871495	15 June 2005	EP				
	WO2006/060878	15 Jun 2006	PCT				
	WO2008/045437	17 Apr 2008	PCT				
	WO2009/091826	23 Jul 2009	PCT				
	WO/2010/025177	04 Mar 2010	PCT				
	WO/2010/085660	29 Jul 2010	PCT				
	WO2011/059836	19 May 2011	PCT				
	WO2012/033885	15 Mar 2012	PCT				
	WO2012/058460	03 May 2012	PCT				
	WO2012/082841	21 Jun 2012	PCT				
	WO2012/127464	27 Sep 2012	PCT				
	WO2012/135854	04 Oct 2012	PCT				
	WO2012/138858	11 Oct 2012	PCT				
	WO2013/033626	07 Mar 2013	PCT				
	WO2013/040371	21 Mar 2013	PCT				
	WO2013/059593	25 Apr 2013	PCT				

Examiner Signature: /Michael Burkhart/	Date Considered: 04/18/2016
--	---------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Sheet 4 of 10		
Form PTO-1449 U.S. Department of Commerce Information Disclosure Statement	DOCKET NO. 046483-6001US13(01088)	APPLN. NO. To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	GROUP: Not Yet Assigned

FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Subclass	Translation Yes/No/Abstract	
	WO 2001/34843	17 May 2001	PCT			English equivalent of JP2003-517301	
	JP2003-517301	27 May 2003	JP			Yes	
	WO 02/077029	03 Oct 2002	PCT			English equivalent of JP2004-529636	
	JP2004-529636	30 Sep 2004	JP			Yes	

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, etc.)	
	A NCBI Direct Submission NP 000725 dated November 21, 2010
	A NCBI Direct Submission NP 932170.1 dated November 21, 2010
	Baeksgaard et al., "Acute tumor lysis syndrome in solid tumors--a case report and review of the literature." 2003, Cancer Chemother Pharmacol., 51:187-92
	Bondanza et al., "Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes." 2006, Blood 107:1828-1836
	Brentjens et al., "Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15." 2003, Nature Medicine, 9(3): 279-286
	Brentjens et al., "Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts." 2007, Clin Cancer Res 13:5426-5435
	Brentjens et al., "Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias." 2011 Blood 118(18):4817-4828
	Brentjens et al., "Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial." 2010, Mol Ther, 18: 666-8
	Brentjens, et al. "A Phase I Trial for the Treatment of Chemo-refractory Chronic Lymphocytic Leukemia with CD19-Targeted Autologous T Cells." Mol. Therapy, 2008, p. S15, Vol 16, Suppl 1.
	Brocker and Karjalainen, "Signals through T cell receptor- ζ chain alone are insufficient to prime resting T lymphocytes." 1995, J. Exp. Med., 181:1653-1659
	Call, et al., "The T cell receptor: critical role of the membrane environment in receptor assembly and function." 2005, Annu Rev Immunol. 2005, 23:101-125
	Campana et al., "T-Cell Immunotherapy for B-Lineage Acute Lymphoblastic Leukemia Using Chimeric Antigen Receptors That Deliver 4-1BB-Mediated Costimulatory Signals" 2003 Blood 102(11); abstract #223
	Carpenito et al., "Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains." 2009, Proc Natl Acad Sci U S A 106:3360-3365

Examiner Signature: /Michael Burkhardt/	Date Considered: 04/18/2016
---	---------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant(s).

Sheet 5 of 10		
Form PTO-1449 U.S. Department of Commerce Information Disclosure Statement	DOCKET NO.	APPLN. NO.
	046483-6001US13(01088)	To Be Assigned
	APPLICANT:	
	Carl H. June et al.	
	FILING DATE:	GROUP:
	Herewith	Not Yet Assigned

OTHER DOCUMENT(S) <i>(Including Author, Title, Date, Pertinent Pages, etc.)</i>	
	Davila et al., "B Cell Aplasia In a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia Following Re-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen." 2010 ASH Meeting Abstract No. 3268, presented December 6, 2010 (poster abstract)
	Davila et al., "T Cells Genetically Targeted to CD19 Eradicate B-All in a Novel Syngeneic Mouse Disease Model." 2010 ASH Meeting Abstract No. 171, presented December 6, 2010 (poster abstract)
	Dohner et al., "p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias." 1995, Blood, 85: 1580-9
	Dropulic et al., "Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome." 2006, Human Gene Therapy, 17: 577-88
	Dull et al., "A third-generation lentivirus vector with a conditional packaging system." 1998, J Virol, 72: 8463-71
	Eshhar et al., "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the Y or ζ subunits of the immunoglobulin and T-cell receptors." 1993, Proc Natl Acad Sci USA 90:720-724
	Finney et al., "Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 (4-1BB) in series with signals from the TCR zeta chain." 2004, J. Immunol 172:104-113.
	Finney et al., "Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product." 1998, J Immunol 161:2791-2797
	Friedmann-Morvinski et al., "Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation." 2005, Blood 105:3087-3093
	Geiger and Jyothi, "Development and application of receptor-modified T lymphocytes for adoptive immunotherapy." 2001, Transfusion Medicine Reviews, 15(1): 21-34
	Geiger et al., "Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes," 2001, Blood 98(8):2364-71
	Gilham et al., "Primary Polyclonal Human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3 ζ - based chimeric immune receptors." 2001, J. Immunology, 25(2): 139-151
	Gong et al., "Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen." 1999, Neoplasia, 1(2): 123-127
	Gribben et al., "Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia." 2011, Biol Blood Marrow Transplant, 17: Suppl:S63-S70
	Griffin et al., "Development and application of surface-linked single chain antibodies against T-cell antigens." 2001, J. Immunological Methods, 248: 77-90
	Gross and Eshhar, 1992, "Endowing T cells with antibody specificity using chimeric T cell receptors." 1992, FASEB J. 6: 3370-3378
	Hallek et al., "Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines." 2008, Blood 111(12):5446-5456

Examiner Signature:	/Michael Burkhart/	Date Considered:	04/18/2016
----------------------------	--------------------	-------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant(s).

Sheet 6 of 10		
Form PTO-1449 U.S. Department of Commerce Information Disclosure Statement	DOCKET NO. 046483-6001US13(01088)	APPLN. NO. To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	GROUP: Not Yet Assigned

OTHER DOCUMENT(S) <i>(Including Author, Title, Date, Pertinent Pages, etc.)</i>	
	Hekele et al., "Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera." 1996, Int J Cancer 68:232-238
	Ho et al., "Adoptive Immunotherapy: Engineering T cell responses as biological weapons for tumor mass destruction." 2003, Cancer Cell 3:431-437
	Hollyman et al., "Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy." J. Immunother., 2009, pp. 169-180, Vol 32, No. 2.
	Homback et al., "The Recombinant T Cell Receptor Strategy: Insights into Structure and Function of Recombinant Immunoreceptors on the Way Towards an Optimal Receptor Design for Cellular Immunotherapy," 2002 Current Gene Therapy 2:211-226
	Imai et al., "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia." 2004, Leukemia 18(4):676-684
	Imai et al., 2005, Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells, Blood, 106:376-383
	International Search Report for PCT/US2011/064191 dated 05/01/2012.
	Irving & Weiss, "The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways." 1991, Cell 64:891-901.
	Jena et al., "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor." 2010, Blood, 116: 1035-44
	Jensen et al., "Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans." 2010 Biol Blood Marrow Transplant 16:1245-1256
	Johnson et al., "Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen." 2009, Blood, 114: 535-46
	June et al., "Engineering lymphocyte subsets: tools, trials and tribulations." 2009, Nat Rev Immunol, 9: 704-16
	Kalos, et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia." 2011, Sci Transl Med 3(95):95ra73
	Kershaw et al., "A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer." 2006, Clin Cancer Res 12:6106-6115
	Kim et al., "Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses." 1998, Eur J Immunol 28:881-890
	Kochenderfer et al., "Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor." 2009, J Immunother 32(7)689-702
	Kochenderfer, et al., "A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells." 2010 ASH Meeting Abstract No. 2865, presented December 5, 2010 (poster abstract)
	Kochenderfer, et al., "Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells." 2010, Blood, 116(9)3875-3886

Examiner Signature: /Michael Burkhardt/	Date Considered: 04/18/2016
---	---------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant(s).

Sheet 7 of 10		
Form PTO-1449 U.S. Department of Commerce Information Disclosure Statement	DOCKET NO. 046483-6001US13(01088)	APPLN. NO. To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	GROUP: Not Yet Assigned

OTHER DOCUMENT(S) <i>(Including Author, Title, Date, Pertinent Pages, etc.)</i>	
	Kochenderfer, et al., "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19." 2010, Blood 116:4099-4102
	Kochenderfer, et al., "Novel Antigen-Specific Expansion of T Cells Transduced with a CD19 Chimeric Antigen Receptor." 2010 ASH Meeting Abstract No. 3262, presented December 6, 2010 (poster abstract)
	Kohn, et al., "CARs on track in the clinic." 2011, Molecular Ther 19(3):432-438
	Krause et al., "Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes." 1998, J. Exp. Med., 188(4): 619-626
	Lamanna et al., "Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia." 2006, J Clin Oncol, 24: 1575-81
	Lamers et al., "Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience." 2006, J Clin Oncol 24:e20-e22
	Laport et al., "Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation." 2003, Blood 102: 2004-2013
	Lee et al., "In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy." 2011, Cancer Res 71:2871-2881
	Letourneur & Klausner, "T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins." 1991, Proc Natl Acad Sci U S A 88:8905-8909.
	Levine et al., "Gene transfer in humans using a conditionally replicating lentiviral vector." 2006, Proc Natl Acad Sci U S A 103:17372-17377
	Macallan et al., "Measurement and modeling of human T cell kinetics." 2003, Eur J Immunol, 33: 2316-26
	Maher et al., "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor." 2002, Nat Biotechnol 20(1):70-5
	McGuinness, et al., "Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor." 1999, Hum.Gene Ther 10:165-173.
	Milone et al., "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo." 2009, Mol Ther 17(8):1453-64
	Molina, "A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma." 2008, Ann Rev Med, 59: 237-50
	Morgan et al., "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2." 2010, Mol Ther, 18: 843-51
	Moritz & Groner, "A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity," 1995, Gene Therapy, 2:539-546

Examiner Signature: /Michael Burkhart/	Date Considered: 04/18/2016
--	---------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant(s).

Sheet 8 of 10		
Form PTO-1449 U.S. Department of Commerce Information Disclosure Statement	DOCKET NO. 046483-6001US13(01088)	APPLN. NO. To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	GROUP: Not Yet Assigned

OTHER DOCUMENT(S) <i>(Including Author, Title, Date, Pertinent Pages, etc.)</i>	
	Moritz et al., "Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells" 1994, Proc. Natl. Acad. Sci. 91:4318-4322
	Naldini et al., "In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector." 1996, Science, 272: 263-7
	Nicholson, et al., "Constructions and Characterization of a Functional CD19 Specific Single Chain Fv Fragment for Immunotherapy of B Lineage Leukemia and Lymphoma." Mol. Immunol., 1997, pp. 1157-1165, Vol 34, No. 16-17.
	Ochoa et al., Immune Defects In T Cells From Cancer Patients, Parallels In Infectious Diseases, from: Cancer Immunotherapy at the Crossroads: how tumors evade immunity and what can be done (current clinical oncology), edited by James H. Finke, Ronald M. Bukowski,, 2004 edition.
	Park and Brentjens, "Adoptive Immunotherapy for B-cell Malignancies with Autologous chimeric Antigen Receptor Modified Tumor Targeted T Cells." 2010, Discov Med 9(47):277-288
	Park et al., "Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma." 2007, Mol Ther 15:825-833
	Patel et al., "Impact of chimeric immune receptor extracellular protein domains on T cell function." 1998, Gene Therapy, 6: 412-419
	Porter et al, "A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation." 2006, Blood, 107:1325-31
	Porter et al., "Chimeric Antigen Receptor Therapy for B-cell Malignancies. 2011, J Cancer 2:331-332
	Porter, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia." 2011 New England J Med 365(8):725-733
	Pule et al., "Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma." 2008, Nat Med 14:1264-1270
	Rapoport et al., "Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer." 2005, Nat Med 11:1230-1237
	Roederer, "T-cell dynamics of immunodeficiency." 1995, Nat Med, 1: 621-7
	Romeo & Seed, "Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides." 1991, Cell 64:1037-1046
	Sabbagh et al., "TNF family ligands define niches for T cell memory." 2007, Trends Immunol 28:333-339
	Sadelain et al., "Targeting tumours with genetically enhanced T lymphocytes." 2003, Nat Rev Cancer 3(1):35-45
	Sadelain et al., "The promise and potential pitfalls of chimeric antigen receptors." 2009, Curr Opin Immunol, 21: 215-23
	Savoldo et al., "CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients." 2011, J Clin Invest 121(5):1822-6
	Sebestyen, et al., "Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer." 2008, J Immunol. 2008, 180(11):7736-46

Examiner Signature: /Michael Burkhardt/	Date Considered: 04/18/2016
--	------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Sheet 9 of 10		
Form PTO-1449 U.S. Department of Commerce Information Disclosure Statement	DOCKET NO. 046483-6001US13(01088)	APPLN. NO. To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	GROUP: Not Yet Assigned

OTHER DOCUMENT(S) <i>(Including Author, Title, Date, Pertinent Pages, etc.)</i>	
	Song, et al. "CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo." 2011 Blood 119:696-706
	Sorrer et al., "Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia." 2008, Blood, 111: 446-52
	Tammana Syam et al., "4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies." 2010 Human Gene Therapy 21:75-86
	Till et al., "Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells." 2008, Blood, 112, 2261-2271
	Uckun, et al., "Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins." 1988, Blood, 71:13-29
	Vinay and Kwon, "Role of 4-1BB in immune responses." 1998, Seminars in Immunology, 10:481-489
	Willemsen et al., "Genetic Engineering of T Cell Specificity for Immunotherapy of Cancer." 2003, Human Immunology, 64: 56-68
	Zufferey et al., "Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo." 1997, Nature Biotechnology 15:871-875
	Chinese Patent Application No. 201180067173.X – Office Action dated October 22, 2014
	Chinese Patent Application No. 201180067173.X – Second Office Action dated July 10, 2015
	Colombia Patent Application No. 13-137636 – Colombian resolution no. 8176 dated February 27, 2015
	Colombia Patent Application No. 13-137636 – English translation of Office Action of September 5, 2014
	Cuba Patent Application No. 2013/0079 Office Action of April 1, 2014
	Cuba Patent Application No. 2013/0079 Office Action of October 28, 2014
	Eurasian Region Patent Application No. 201390847/28 Office Action dated March 11, 2015
	European Patent Appl 11846757.0 European Search Report of December 2, 2014
	European Patent Application No. 11846757.0 – Office Action dated August 17, 2015
	Guatemala Patent Application No. A-2013-150 – English translation of Observer's comments of September 17, 2014.
	Japanese Patent Application No. 2013-543380 – Office Action dated October 15, 2015
	Mexican Patent Application No. MX/a/2013/006570 – Office Action dated October 9, 2015
	New Zealand Patent Application No. 612512 - First Exam Report of November 20, 2013
	Thailand Patent Application No. 1301003120 – Office Action of July 2014
Examiner Signature: /Michael Burkhart/	Date Considered: 04/18/2016

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Sheet 10 of 10		
Form PTO-1449 U.S. Department of Commerce Information Disclosure Statement	DOCKET NO. 046483-6001US13(01088)	APPLN. NO. To Be Assigned
APPLICANT: Carl H. June et al.		
FILING DATE: Herewith		GROUP: Not Yet Assigned

OTHER DOCUMENT(S) <i>(Including Author, Title, Date, Pertinent Pages, etc.)</i>		
		U.S. Patent Application No. 14/107,302 – Final Office Action of March 31, 2015
		U.S. Patent Application No. 14/107,302 - non-final Office Action of September 30, 2014
		U.S. Patent Application No. 14/567,426 - non-final Office Action of January 16, 2015
		U.S. Patent Application No. 14/568,195 - non-final Office Action of January 30, 2015
		U.S. Patent Application No. 14/568,569 - non-final Office Action of January 15, 2015
		U.S. Patent Application No. 13/992,622 - non-final Office Action of June 19, 2015
		U.S. Patent Application No. 13/992,622 – Final Office Action of January 5, 2016
		U.S. Patent Application No. 14/465,952 – non-final Office Action of November 20, 2014
		U.S. Patent Application No. 13/938,923 – Final Office Action mailed March 28, 2014
		U.S. Patent Application No. 13/938,923 – Final Office Action mailed October 8, 2014
		U.S. Patent Application No. 13/938,923 - non-final Office Action of September 19, 2013
		U.S. Patent Application No. 13/938,947 - Final Office Action of September 11, 2014
		U.S. Patent Application No. 13/938,947 - non-final Office Action of December 16, 2013
		U.S. Patent Application No. 14/466,096 – non-final Office Action of October 8, 2014

Examiner Signature: /Michael Burkhart/	Date Considered: 04/18/2016
---	------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

UPenn Ex. 2026
Miltenyi v. UPenn
IPR2022-00855
Page 10